Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of ADCs in cancerous cells while avoiding the release of their toxic payloads in healthy ones. This promises to increase efficacy of these therapies in a wide range of cancers without causing unacceptable side-effects. We spoke to Brian Fiske, co-founder, chief scientific officer of Mythic, about the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.
Using a Digital Cognitive Behavior Therapy to Treat Diabetes and Heart Disease
Disrupting Pain Signals with Precision
A Diagnostics Company Moves to Developing Precision Cancer Therapies
Characterizing the Immunome at Scale
Delivering Oxygen to Tissue in Need
Using Gene Therapy to Create a Drug Biofactory within a Patient
Finding New Uses for TNF Inhibitors
Using AI to Map the Undiscovered World of Bioactive Compounds in Plants
Improving the Delivery of Drugs through Thin Film Freezing
Using CRISPR to Target RNA Instead of DNA
An Antisense Pioneer Brings Custom Treatments to Patients with Ultra-Rare Conditions
Managing Neurodegenerative Diseases with Better Data to Improve Outcomes
A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response
Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer
Bringing Innovation to Cell and Gene Therapy Manufacturing
Tapping Psychedelics for their Anti-Inflammatory Powers
Advancing Cell Therapies Beyond Cancer
How the Pandemic Transformed a Small Diagnostics Company
Eliminating Security, Privacy, and Regulatory Burdens with Synthetic Data
Using Computational Discovery to Build Better Immunotherapies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind